Thanks! .. and your welcome, glad you find it helpful. … I like to go back and relisten to CC’s, the break down makes it’s helpful when searching for scientific data slides for example etc
For example ..,at the 21:36 time mark is a photo of lung x-rays. I was looking for this particular thing to show some one …having the below mapped out it made for easy reference ….
** link to the CC at bottom of this post
4:45 start time 6:20 begin investors Q&A 7:00 SEC discussed 7:31 Auditor change / 8k item 4.01 discussed 813 OTC OTCQB discussed 8:56 Farmatsevtik Armenia 13:40 QNTA Main GOALS & PLANS 17:35 some Paxlovid users had symptoms relapse, versus with escozine symptoms did not return 18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal” 20:22 CHART escozine therapy results EFFICACY charts 21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine 22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid 26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<< 31:38 slide shown Escozine BLOCKS omicron 32:50 “beauty of Escozine” 33:30 explains COVID registration PROCESS versus CANCER Registration process 35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP ) 36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study 37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again) 38:06 *** FDA strategy summarized “Actively working to completely FDA process” *** Funding discussed to finished indoor facility in DR 41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” *** 42:00 investor engaging with FDA LOBBYIST to help FDA process ** investor has experience w distribution of Covid 19 vaccines 42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status 43:08 a vision for DISTRIBUTION and New Opportunities 46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned 49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped 50:00-51:54 *LICENSING discussed* (noted / reminder in the CC big pharma moves slow / process takes time) 51:56 name & SYMBOL CHANGE addressed 52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood) 53:57 “Shared CEO” position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ - roles of co-ceo positions discussed 55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind # 56:45 dispels myth of his salary 57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination of research to where qnta is now and moving forward toward to a continued path to achieving goals *** As always, one should do DD Listen to the CC. Read the data etc GLTA *** Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Market Data 
Markets 
AI
